Indeed, ribosomal inhibition using homoharringtonine (HHT) or disruption of the interaction between eIF4E and eIF4G using SBI-0640756 or 4EGI-1 reduces MCL-1 and BCL-XL levels in MCL cell lines and primary CLL cells and potentiated the activity of BH3-mimetics [67–69]. The gene discussed is BCL2L1; the disease is B-cell chronic lymphocytic leukemia.